Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.

Forgot your password?

Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.

I agree to TheMaven'sTerms andPolicy

Already have an account? Login here

JIM CRAMER INVESTING PERSONAL FINANCE RETIREMENT TECHNOLOGY MARKETS HOW-TO VIDEO FINANCIAL ADVISOR CENTER

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

Y-mAbs Announces Sale Of Priority Review Voucher

By GlobeNewswire
Dec 28, 2020 9:00 AM EST

Y-mAbs Announces Pipeline Update

By GlobeNewswire
Dec 16, 2020 9:00 AM EST

Y-mAbs Announces Update On DANYELZA® (naxitamab-gqgk) At ESMO

By GlobeNewswire
Dec 9, 2020 9:00 AM EST

FDA Approves Y-mAbs' DANYELZA® (naxitamab-gqgk) For The Treatment Of Neuroblastoma

By GlobeNewswire
Nov 25, 2020 5:02 PM EST

Y-mAbs Announces Update On Omburtamab In DIPG

By GlobeNewswire
Nov 19, 2020 9:00 AM EST

Y-mAbs Announces FDA Clearance Of IND For Lutetium-177 Labeled Omburtamab Antibody For Adult Indications

By GlobeNewswire
Oct 26, 2020 9:10 AM EDT

Y-mAbs Announces Update On Naxitamab And Omburtamab In Neuroblastoma

By GlobeNewswire
Oct 16, 2020 9:00 AM EDT

Y-mAbs Announces FDA Clearance Of IND For Its Lutetium-177 Labeled Omburtamab Antibody

By GlobeNewswire
Oct 14, 2020 9:00 AM EDT

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Y-mAbs Therapeutics, Inc. - YMAB

By PR Newswire
Oct 8, 2020 6:13 PM EDT

Y-mAbs' Nivatrotamab For The Treatment Of Patients With Neuroblastoma Granted Orphan Drug Designation And Rare Pediatric Disease Designation By FDA

By GlobeNewswire
Oct 7, 2020 9:00 AM EDT

Y-mAbs Provides Regulatory Update On Omburtamab For The Treatment Of Patients With Neuroblastoma

By GlobeNewswire
Oct 5, 2020 4:01 PM EDT

Y-mAbs Announces Completion Of Submission Of Omburtamab Biologics License Application To FDA

By GlobeNewswire
Aug 6, 2020 9:00 AM EDT

Y-mAbs Announces Data To Be Presented At 2020 SIOP

By GlobeNewswire
Jul 27, 2020 4:01 PM EDT

Y-mAbs Announces Update On SADA Technology And New Preclinical SADA Construct

By GlobeNewswire
Jul 14, 2020 9:00 AM EDT

Y-mAbs Announces Initiation Of Submission Of Omburtamab Rolling Biologics License Application To The FDA

By GlobeNewswire
Jun 30, 2020 4:01 PM EDT

Y-mAbs Announces U.S. FDA Acceptance Of Biologics License Application For Danyelza™ (naxitamab) For The Treatment Of Neuroblastoma For Priority Review

By GlobeNewswire
Jun 2, 2020 9:00 AM EDT

Y-mAbs Announces Data To Be Presented At 2020 ASCO Annual Meeting

By GlobeNewswire
May 13, 2020 9:00 AM EDT

Y-mAbs Announces Appointment Of Laura J. Hamill To Its Board Of Directors

By GlobeNewswire
Apr 24, 2020 9:00 AM EDT

Y-mAbs Announces Submission Of Naxitamab Biologics License Application To U.S. FDA

By GlobeNewswire
Apr 1, 2020 9:00 AM EDT

Y-mAbs To Announce 2019 Financial And Operating Results On March 12, 2020

By GlobeNewswire
Mar 5, 2020 9:00 AM EST

Y-mAbs Announces Positive Pre-BLA Meeting With FDA For Omburtamab

By GlobeNewswire
Feb 26, 2020 4:01 PM EST

Terms Of Use
Privacy Policy
Advertise
Reprints
Customer Service
Data
Topic Archive
Subscriptions

© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.